Athira Pharma, Inc. Stock Price, News & Analysis

Athira Pharma (NASDAQ: ATHA) has initiated patient dosing in the SHAPE Phase 2 clinical trial for ATH-1017, targeting Parkinson's disease dementia and Dementia with Lewy bodies. ATH-1017 aims to enhance Hepatocyte Growth Factor (HGF) activity to address neurodegeneration. The randomized trial will enroll 75 participants in the U.S., assessing cognitive, functional, and behavioral endpoints over 26 weeks. Current therapies for these conditions are limited, highlighting a significant need for innovative treatments.

Athira Pharma (NASDAQ: ATHA) reported progress in its clinical programs and outlook for 2022, highlighting the ACT-AD Phase 2 study with topline data expected in 2Q22. The LIFT-AD Phase 3 study of ATH-1017 in Alzheimer's disease is expanding enrollment from 300 to 420 participants to bolster statistical power for secondary endpoints, aiming for top-line data by 1H23. Additionally, the SHAPE Phase 2 trial for Parkinson's disease dementia was initiated, while an IND application for ATH-1020 has been filed. The company anticipates robust developments across its pipeline, focusing on neurodegenerative diseases.

Athira Pharma (NASDAQ: ATHA) announced its third quarter 2021 financial results, highlighting a cash position of $339.4 million. The company completed enrollment in the ACT-AD trial, with topline data expected in H1 2022, while the LIFT-AD trial is actively recruiting, aimed for completion by 2022. R&D expenses rose to $10.7 million compared to $5.8 million in 2020. The net loss increased to $15.7 million ($0.42 per share) from $8.5 million ($1.12 per share) in the same quarter the previous year.

Athira Pharma (NASDAQ: ATHA) announced progress on its late-stage clinical trials for ATH-1017, aimed at treating mild-to-moderate Alzheimer’s disease, during the CTAD conference in Boston. Both trials, ACT-AD and LIFT-AD, are randomized and placebo-controlled, showing balanced baseline characteristics and encouraging safety profiles. Topline data from the ACT-AD trial is expected in the first half of 2022, providing insights on cognitive function and neurodegeneration. The company emphasizes the potential of ATH-1017 in addressing unmet patient needs in Alzheimer's treatment.

Athira Pharma (NASDAQ: ATHA) announces participation in two investor conferences: the Stifel 2021 Virtual Healthcare Conference on November 15 at 2:40 p.m. ET and the Jefferies 2021 London Healthcare Conference available on-demand from November 18 at 4:00 a.m. ET. Both events will feature a fireside chat format. Live webcasts will be accessible through the Investors section of the Athira website, with archived replays available for 30 days. Athira focuses on developing small molecules to restore neuronal health and combat neurodegeneration, particularly in Alzheimer’s and Parkinson’s.

Athira Pharma (NASDAQ: ATHA) announced an upcoming webinar featuring neurologist Dr. John Michael Olichney. The event is scheduled for Friday, Nov. 5, at 9 a.m. PT / 12 p.m. ET, focusing on the P300 latency measure for assessing cognitive function and its correlation with working memory. Key presentations will also include insights from Kevin Church on ATH-1017, a small molecule therapeutic for Alzheimer’s and Parkinson’s dementia, and Hans Moebius on the ongoing ACT-AD trial. The trial's topline data is expected in early 2022.

Athira Pharma (NASDAQ: ATHA) has completed enrollment for its Phase 2 ACT-AD clinical trial, investigating ATH-1017 for mild-to-moderate Alzheimer’s disease. The trial enrolled 77 patients across the U.S. and Australia to evaluate cognitive improvements over 26 weeks. Topline results are expected in the first half of 2022. CEO Mark Litton emphasized the significance of this milestone, noting the potential for ATH-1017 to offer new treatment options. The company also plans to initiate a clinical trial for Parkinson’s disease dementia later this year.

Athira Pharma announced the appointment of Mark Litton, Ph.D., M.B.A., as the new CEO, succeeding Dr. Leen Kawas, who has resigned amid an investigation into allegations regarding her doctoral research. The special committee found that Dr. Kawas altered images in her past research, but clarified that this did not involve the company’s lead candidate, ATH-1017. This candidate is currently in late-stage development for Alzheimer’s treatment, with promising results from prior trials. The company emphasizes its commitment to integrity and scientific research.

Athira Pharma (NASDAQ: ATHA) announced updates on its ongoing Phase 2 and Phase 2/3 clinical trials for ATH-1017, a small molecule therapeutic targeting Alzheimer’s disease. The data will be presented at the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) conference from Nov. 9-12, 2021. The presentation, titled "Phase 2/3 trials of ATH-1017," will be delivered by CMO Hans Moebius on Nov. 10 at 1:55 p.m. ET.